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Available online 14 April 2016The human embryonic stem cell line RCe016-A (RC-12) was derived under quality assured compliance with UK
regulations, EU Directives and International guidance for tissue procurement, processing and storage according
to good manufacturing practice (GMP) standards. The cell line was derived from a cryopreserved blastocyst
stage embryo voluntarily donated as surplus to fertility requirements following informed consent. RCe016-A
(RC-12) shows normal pluripotency marker expression and differentiation to three germ layers in vitro.
Karyology revealed a mixed male karyotype at early passage (P15), which resolved as normal 46XY by passage
33. Microsatellite PCR identity, HLA and blood group typing data is available.
© 2016 Roslin Cells Ltd. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Li
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RCe016-A (RC-12) was derived from a frozen and thawed blastocyst
stage embryo that was surplus to fertility treatment requirements.
Human embryonic stem cell (hESC) isolation, expansion and qualiﬁca-
tion were performed in facilities whose speciﬁcation, operation and
monitoring complied with GMP standards enabling; i) a fully traceable
procurement procedure with informed ethical consent which includes
provision for commercial use, ii) detailed medical history and blood
borne virus (BBV) screening of donors, and iii) compilation of a cell
line history providing details on the hESC manufacturing process and
quality control testing regime.
Human ESC culture and processing were performed in a grade A
tissue culture cabinet in a grade B clean room environment monitored
for particulate and microbiological contamination during cell process-
ing in accordance with the Rules and Guidance for Pharmaceutical
Manufacturers and Distributors — The Orange Guide, compiled by
the UK Medicines Healthcare Products Regulatory Authority (go to:mmons.org/licenses/by/4.0/).
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distribution-practice). Accordingly, the facility was operating under a
mature Quality Management System, compliant with ISO9001:2008
standards. HESC derivation was performed under licensure from the
UK HFEA (R0136 to centre 0202) and HTA (Licensing Number 22631).
HESC derivation involved whole embryo outgrowth on mitoti-
cally inactivated human dermal ﬁbroblast (HDF) feeder cells. HDFs
were derived and manufactured according to GMP and had been
approved for clinical use by the Food and Drug Administration,
USA. During derivation on HDFs, hESCs were grown in a xeno-free
cell therapy grade media (XF KODMEM) supplemented with xeno-
free human recombinant bFGF. HESCs were subsequently expanded
in a GMP grade serum-free medium (StemPro hESC Serum Free
Medium) on a xeno-free matrix (CellStart). The former contained
bovine serum albumin (BSA) from a transmissible spongioform
encephalopathy (TSE)-free country of origin. The cell line was cryo-
preserved in a GMP compliant cryopreservation solution (CryoStor
CS10).
By ﬂow cytometry, RCe016-A (RC-12) expressed the pluripotency
makers Oct-4, Tra-1-60 and SSEA-4 (88.8%, 85.8% and 95.0%,Fig. 1. Quality Control Certiﬁcate of Analysrespectively), whereas low expression of the differentiation marker
SSEA-1 (0.1%) was observed (Figs. 1, 2). Differentiation to the three
germ layers, endoderm, ectoderm and mesoderm, was demonstrat-
ed using embryoid body formation in vitro, and expression of the
germ layer markers α-fetoprotein, β-tubulin and muscle actin was ob-
served (Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group AO1 (Table 1).Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed a mixed male genotype at passage 15 (Certiﬁcate of Analysis,
Fig. 1). A normal 46XY genotype was present in 18 of 30 cells analysed,
but a subpopulation (12 of 30 cells) exhibited trisomy 12 (47XY, +12).
By passage 33, the cell line had stabilised on a normal male 46XY karyo-
type (Fig. 4). The cell line is free from mycoplasma contamination as
determined by RT-qPCR.is for RCe016-A (RC-12) P8B seed lot.
Fig. 1 (continued).
772 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 770–775Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to fertilise/
develop embryos was approved by The Scotland A Research EthicsFig. 2. RCe016-A (RC-12) was subjected to ﬂow cytometry analysis for markers of pluripotency
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (Fig. 1).Committee and local ethics board at participating fertility clinics and con-
ducted under licence no. R0136 from the UK HFEA with informed donor
consent. The processing and storage of hESC cells for human application
were conducted under licence no. 22631 from the UK Human Tissue
Authority.with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
Fig. 3. In vitro differentiation of RCe016-A (RC-12) to ectoderm (β-tubulin III), mesoderm (muscle actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green; cell nuclei are
counterstained with DAPI (blue).
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Frozen embryos were thawed using a Vitriﬁed Embryo Safety
Thawing Pack (Kitazato/Dibimed, Valencia, Spain) according to
the manufacturers' instruction and were cultured in system SAGE
Quinn's Advanced Blastocyst medium (Rochford Medical, Coven-
try) after day 3 of development. Embryos were cultured at 36.5–
37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in drops under parafﬁn
oil (Rochford Medical) and transferred to fresh medium at least
every 2–3 days.
By Day 8 of development, embryos were placed in derivation
conditions consisting of mitotically inactivated GMP grade neonatal
human dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on
tissue culture plastic in XF KODMEM medium (Knockout-DMEM,
15% KOSR-XF, 2 mM L-glutamine, 1% MEM nonessential amino
acids, 2% XF Growth Factor Cocktail, 0.1 mM β-mercaptoethanol
(ThermoFisher Scientiﬁc, Paisley, UK)) supplemented with 80 ng/ml
human bFGF (ThermoFisher Scientiﬁc). When available, cell therapy
system quality reagents were used. Assisted hatching was performed
by removing the zona pellucidae mechanically using Swemed cutting
tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10%
Pharma grade FCS (GE Healthcare (PAA), Buckinghamshire, UK)
and 2mML-glutamine (ThermoFisher Scientiﬁc). HDFsweremitotically
inactivated using gamma irradiation at 50 Gy using a Gammacell Elite
1000 machine. For use as a feeder layer, irradiated HDFs were plated
at 50,000 cells/cm2 in XF KODMEM medium supplemented withTable 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe016-A (RC-12).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2
16 17 17 18
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2
X Y 13 13
D19S433 1 D19S433 2 THO1 1 THO1 2
14 14 7 8
D5S818 1 D5S818 2 D7S820 1 D7S820 2
12 13 11 11
Blood group genotyping
RhD RhC Rhc RhE
pos neg pos neg
Jka Jkb K k
neg pos neg pos
Do a Do b ABO
neg pos AO1
HLA tissue typing
HLA Class I Type HLA-A*01, A*11; B*08, B*35; Cw*04, Cw*07
HLA Class II Type HLA-DRB1*03, DRB1*04; DRB3*01; DRB4*01; DQB1*02, DQB1*03; D
Comment DRB1*03 is expressed serologically as DR17, DQB1*03 is expressed80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium
exchanged 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (cell therapy system
quality reagents, ThermoFisher Scientiﬁc). Passaging was performed
mechanically using an EZ passage tool (ThermoFisher Scientiﬁc). hESC
lines were expanded to 25–30wells of a 6-well plate and cryopreserved
in 0.5–1 ml Cryostor CS10 (Biolife Solution, Washington, USA) using
an EF600-107 controlled rate freezer (Grant Instruments, Cambridge,
UK) before being stored in a−150 °C freezer (Panasonic Biomedical,
Loughborough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™Mycoplasma Real-Time PCR Detection Kit (ThermoFisher
Scientiﬁc (Applied Biosystems)) according to the manufacturers'
instruction. European Pharmacopoeia (EP) mycoplasma testing was
carried out by Moredun Scientiﬁc Ltd. (Edinburgh, UK), under a quality
and technical agreement.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according toD16S539 1 D16S539 2 D2S1338 1 D2S1338 2
9 11 24 25
D21S11 1 D21S11 2 D18S51 1 D18S51 2
27 29 11 14
FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
23 26 12 12
D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 13 8 11
Rhe Fy a Fy b Fy GATA
pos pos pos neg
M N S S
pos neg neg pos
PB1*04
serologically as DQ8, unable to exclude DPB1*2302 N/2402/9901.
Fig. 4. RCe016-A (RC-12) was analysed by Giesma staining of 20 metaphase spreads at passage 33 and showed a normal male karyotype of 46XY.
774 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 770–775the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%, and the reaction time of
the negative control was greater than the reaction time of the lowest
standard on the standard curve.
Flow cytometry
Pluripotency was determined using the Human and Mouse
Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct-3/4 and
SSEA-4 were included as pluripotency markers, and SSEA-1 as a dif-
ferentiation marker. FITC conjugated Tra-1-60 (BD) was used as an
additional pluripotency marker. Fixed and permeabilised cells
were analysed using a FACS Aria ﬂow cytometer (BD) or a Guava
easyCyte ﬂow cytometer (Millipore, Watford, UK). Percentage
expression of each marker was compared to isotype control or
unstained cells.
Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy,
the Guava Viacount reagent (Millipore) containing a nuclear and a via-
bility dye, was mixed with a single cell suspension, incubated for 5 min
and analysed using the Guava easyCyte ﬂow cytometer (Millipore).
Total cell count, viable cell count and percentage viable cells were
obtained.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 daysbefore being transferred into EB medium (20% FBS (GE Healthcare
(PAA)), 80% KO-DMEM 1 mM L-glutamine, 3.5 μM β-mercaptoethanol,
and 1% nonessential amino acids (all ThermoFisher Scientiﬁc)), on
glass slide tissue culture chambers (Nunc, ThermoFisher Scientiﬁc)
coated with 0.2% gelatin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for
14 days.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scientiﬁc)
and stained with AFP (1:500; Sigma), β-tubulin III (1:1000; Sigma) and
muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark) and secondary
antibody antimouse IgG-AlexaFluor 488 (1:200; Sigma). Images were
acquired using a Zeiss S100 Axiovert ﬂuorescence microscope or a Nikon
eC1 confocal microscope.
Genomic analysis and outsourced assays
All outsourced assays were carried out under a quality and technical
agreement. DNAwas extracted using theQIAampDNAMini kit (Qiagen,
Manchester, UK) according to the manufacturer's recommendations
and provided in recommended quantities to the service providers.
Microsatellite PCR or short tandem repeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human leukocyte antigen (HLA) tissue typingwas carried out by the
Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
775P.A. De Sousa et al. / Stem Cell Research 16 (2016) 770–775(Edinburgh, UK). Live cells at 60–70% conﬂuencywere shipped inwarm
containers, ﬁxed and analysed by standard G-banding analysis. For clin-
ical grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell lym-
photropic virus (HTLV), Human immunodeﬁciency virus (HIV)-1,
Hepatitis C virus (HCV), Hepatitis B virus (HBV), Epstein–Barr virus
(EBV) and syphilis was carried out by The Doctors Laboratory.Acknowledgements
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